262 related articles for article (PubMed ID: 31533728)
41. Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes.
Sanchez A; Ortega P; Sakhtemani R; Manjunath L; Oh S; Bournique E; Becker A; Kim K; Durfee C; Temiz NA; Chen XS; Harris RS; Lawrence MS; Buisson R
Nat Commun; 2024 Mar; 15(1):2370. PubMed ID: 38499542
[TBL] [Abstract][Full Text] [Related]
42. Genetic Polymorphisms Predisposing the Interleukin 6-Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations.
Liu W; Wu J; Yang F; Ma L; Ni C; Hou X; Wang L; Xu A; Song J; Deng Y; Xian L; Li Z; Wang S; Chen X; Yin J; Han X; Li C; Zhao J; Cao G
Clin Cancer Res; 2019 Sep; 25(18):5525-5536. PubMed ID: 31152021
[TBL] [Abstract][Full Text] [Related]
43. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
44. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases.
Ng JCF; Quist J; Grigoriadis A; Malim MH; Fraternali F
Nucleic Acids Res; 2019 Feb; 47(3):1178-1194. PubMed ID: 30624727
[TBL] [Abstract][Full Text] [Related]
45. DNA replication stress: a source of APOBEC3B expression in breast cancer.
Cescon DW; Haibe-Kains B
Genome Biol; 2016 Sep; 17(1):202. PubMed ID: 27716362
[TBL] [Abstract][Full Text] [Related]
46. Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations and immune activation.
Pan JW; Zabidi MMA; Chong BK; Meng MY; Ng PS; Hasan SN; Sandey B; Bahnu S; Rajadurai P; Yip CH; Rueda OM; Caldas C; Chin SF; Teo SH
Int J Cancer; 2021 May; 148(10):2489-2501. PubMed ID: 33423300
[TBL] [Abstract][Full Text] [Related]
47. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
48. APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
Schmitt C; Lucius R; Synowitz M; Held-Feindt J; Hattermann K
Oncol Rep; 2018 Nov; 40(5):2742-2749. PubMed ID: 30226610
[TBL] [Abstract][Full Text] [Related]
49. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
50. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
51. APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.
DiMarco AV; Qin X; McKinney BJ; Garcia NMG; Van Alsten SC; Mendes EA; Force J; Hanks BA; Troester MA; Owzar K; Xie J; Alvarez JV
Cancer Immunol Res; 2022 Jan; 10(1):70-86. PubMed ID: 34795033
[TBL] [Abstract][Full Text] [Related]
52. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
Cescon DW; Haibe-Kains B; Mak TW
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878
[TBL] [Abstract][Full Text] [Related]
53. Involvement of APOBEC3A/B Deletion in Mouse Mammary Tumor Virus (MMTV)-like Positive Human Breast Cancer.
de Sousa Pereira N; Vitiello GAF; Amarante MK
Diagnostics (Basel); 2023 Mar; 13(6):. PubMed ID: 36980505
[TBL] [Abstract][Full Text] [Related]
54. BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B.
Coelho MA; Li S; Pane LS; Firth M; Ciotta G; Wrigley JD; Cuomo ME; Maresca M; Taylor BJM
BMC Biol; 2018 Dec; 16(1):150. PubMed ID: 30593278
[TBL] [Abstract][Full Text] [Related]
55. Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
Rouf Banday A; Onabajo OO; Lin SH; Obajemu A; Vargas JM; Delviks-Frankenberry KA; Lamy P; Bayanjargal A; Zettelmeyer C; Florez-Vargas O; Pathak VK; Dyrskjøt L; Prokunina-Olsson L
Commun Biol; 2021 Mar; 4(1):386. PubMed ID: 33753867
[TBL] [Abstract][Full Text] [Related]
56. Epstein-Barr Virus-induced Gene 3 as a Novel Biomarker in Metastatic Melanoma With Infiltrating CD8
Yonekura S
Anticancer Res; 2022 Jan; 42(1):511-517. PubMed ID: 34969761
[TBL] [Abstract][Full Text] [Related]
57. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations.
Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS
Nat Commun; 2024 Mar; 15(1):2369. PubMed ID: 38499553
[TBL] [Abstract][Full Text] [Related]
58. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication.
Hoopes JI; Cortez LM; Mertz TM; Malc EP; Mieczkowski PA; Roberts SA
Cell Rep; 2016 Feb; 14(6):1273-1282. PubMed ID: 26832400
[TBL] [Abstract][Full Text] [Related]
59. DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo.
Naumann JA; Argyris PP; Carpenter MA; Gupta HB; Chen Y; Temiz NA; Zhou Y; Durfee C; Proehl J; Koniar BL; Conticello SG; Largaespada DA; Brown WL; Aihara H; Vogel RI; Harris RS
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298259
[TBL] [Abstract][Full Text] [Related]
60. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Walker BA; Wardell CP; Murison A; Boyle EM; Begum DB; Dahir NM; Proszek PZ; Melchor L; Pawlyn C; Kaiser MF; Johnson DC; Qiang YW; Jones JR; Cairns DA; Gregory WM; Owen RG; Cook G; Drayson MT; Jackson GH; Davies FE; Morgan GJ
Nat Commun; 2015 Apr; 6():6997. PubMed ID: 25904160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]